← Leaderboards
David Alexoff
Five Eleven Pharma, Inc.
$1,850,935
Attributed
$1,850,935
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $853.1K · FY2017–20$1M$750K$500K$250K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$1,850,935 · 3
By mechanism
R44$1,400,935 · 1
R43$450,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Site”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Beth Baseler · Leidos Biomedical Research, Inc.$118,180,593
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
Research focus
SitePositron-Emission TomographyLeadRadioisotopesUniversitiesProductionFundingLabelPharmaceutical PreparationsRadiochemicalSmall Business Innovation Research GrantTargeted AgentClinical ResearchBaseDiagnosticCancer PatientDevicesDetectionMalignant Neoplasm Of ProstateMeetingsImageImaging AgentBone ImagingChemistry
Grant awards (5)
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer$248,430
R44 · FY2020 · CA · contact PI
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer$853,093
R44 · FY2019 · CA · contact PI
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer$299,412
R44 · FY2018 · CA · contact PI
A low-cost automated Gallium-68 drug preparation device for diagnostic PET imaging$225,000
R43 · FY2017 · CA · contact PI
Development of novel gallium-68 bisphosphonate for imaging bone metastases in prostate cancer$225,000
R43 · FY2017 · CA · contact PI